A world leading medical journal publishes trial showing breakthrough anti-cold, anti-flu product cuts recurrent colds by more than half. Study results of COLD-fX(R) made public as medical community prepares for cold & flu season.EDMONTON, Oct. 24 /PRNewswire-FirstCall/ -- (CVQ-TSX VEN). The Canadian Medical Association Journal The Canadian Medical Association Journal (CMAJ) is a general medical journal that is published biweekly by the Canadian Medical Association (CMA).
It is considered to be one of the top six general medical journals; the others being the - regarded as one of the five top general medical journals in the world - will tomorrow publish a landmark double-blind, placebo- controlled study on the prevention and relief of upper respiratory infections. The clinical trial was conducted on the breakthrough anti-cold, anti-flu remedy, COLD-fX(R) by Edmonton's Medical Officer of Health and a senior Canadian researcher who called the results 'statistically highly significant'.
The trial results show that COLD-fX(R) reduced the incidence and frequency of recurrent colds by more than half. It also cut the duration of colds and significantly reduced their severity.
The number of upper respiratory infections in each subject was significantly reduced by 25% in the COLD-fX(R) group during the 4 month treatment period. Even more impressive however, was the finding that recurrent infections were reduced by 56% (10.0% in the COLD-fX(R) group v. 22.8% in the placebo group, an absolute difference of 12.8%). COLD-fX(R) treatment also had a significant effect in reducing the total symptom score and the duration of infections. The incidence of adverse events was low and the prevalence was found to be similar between the two groups.
The trial was conducted by internationally respected Nutritional Biochemist, Dr. Tapan Basu, a professor at the University of Alberta, and Edmonton's Medical Officer of Health, Dr. Gerry Predy of Capital Health.
The study involved 323 adults from the general population (18-65 years of age) with a history of at least two upper respiratory infections in the previous year. Participants were given either COLD-fX(R) or a placebo for four months during the winter of 2003/04. Subjects graded the severity and duration of their respiratory-related symptoms on a 4-point scale. All analysis was performed by a University of Western Ontario Western is one of Canada's leading universities, ranked #1 in the Globe and Mail University Report Card 2005 for overall quality of education. It ranked #3 among medical-doctoral level universities according to Maclean's Magazine 2005 University Rankings. biostatistician under blinded conditions.
The authors of the study concluded that the COLD-fX(R) treatment appeared to be an attractive natural prophylactic treatment for upper respiratory infections. Regular intake of COLD-fX(R) was shown in the clinical trial to be effective not only for the prevention of upper respiratory infections, but also for relief of symptoms if an infection did occur. The results were similar to those observed in previous clinical studies on COLD-fX(R).
Dr. Basu said, "One of biggest challenges in clinical studies with natural based compounds is the lack of standardization of the testing material. Most natural health products do not offer batch-to-batch consistency and do not produce consistent clinical results. This trial was unique in that it examined a unique natural extract with the same rigor used for conducting trials of drug candidates in the pharmaceutical industry, a practice that is rarely found in the natural health product business."
"We are interested in the potential positive implications for our residents and the results from clinical trials done to date are encouraging," said Dr. Predy. "For example, in participants taking COLD-fX(R) daily for prevention, recurrent infections were reduced by more than half. In addition, there was a 31% reduction in the severity of their symptoms."
CV Technologies Inc. CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and Chief Scientific Officer and co-discoverer of COLD-fX(R), Dr. Jacqueline Shan said, "This is the first publicly known study to be completed under the new regulations established by Health Canada's Natural Health Product Directorate. We were pleased that the Canadian Medical Association Journal decided to publish the study. Like all published clinical trials it has undergone a rigorous peer-review process by experts chosen by the Journal".
In two previous trials involving 198 nursing home seniors conducted under FDA's drug regulations by Dr. Janet McElhaney, the newly appointed head of geriatric medicine at the University of British Columbia Locations
The Vancouver campus is located at Point Grey, a twenty-minute drive from downtown Vancouver. It is near several beaches and has views of the North Shore mountains. The 7. , COLD-fX(R) showed an 89% reduction in clinical illness caused by influenza and cold viral infection confirmed by virological testing. The four month study conducted while Dr. McElhaney was a professor at Eastern Virginia Medical School also demonstrated an excellent safety profile in that group. The results of that study were published in 2004 in the peer reviewed Journal of the American Geriatrics Society. Eastern Virginia Medical School, in Norfolk, Virginia is a public medical school.
A multi-centre and multi-dosage, double-blind, placebo-controlled clinical trial on COLD-fX(R) involving 720 community living healthy seniors was launched this month in Canada. This trial is being jointly conducted by Dr. Gerry Predy, Medical Officer of Health in Edmonton, Dr. Andrew Simor, a leading infectious disease expert and the head of microbiology at Sunnybrook and Women's College Health Sciences Centre in Toronto and Dr. Janet McElhaney, an internationally recognized influenza expert and head of geriatric medicine at the University of British Columbia in Vancouver.
COLD-fX(R) is a proprietary, commercially available natural health product developed and manufactured by CV Technologies. It is the result of more than ten years of scientific and clinical research by a team of 25 scientists. It is standardized by the company's proprietary ChemBioPrint (CBP CBP
competitive protein binding. (R)) technology to ensure batch-to- batch consistency and efficacy. In lab and clinical studies it has been shown to have an excellent safety profile. According to ACNielsen, it's the No. 1 selling cold/flu remedy in Canada.
ABOUT THE CANADIAN MEDICAL ASSOCIATION JOURNAL:
The CMAJ was founded in 1911 and publishes every 2 weeks. It is distributed to over 60,000 physicians. The CMAJ receives 2,000 manuscripts a year including letters to the editor and news articles. Its acceptance rate for unsolicited research and review articles is about 12%. It is regarded as one of the top five general medical journals in the world - the others being the New England Journal of Medicine The New England Journal of Medicine (New Engl J Med or NEJM) is an English-language peer-reviewed medical journal published by the Massachusetts Medical Society. It is one of the most popular and widely-read peer-reviewed general medical journals in the world. , Journal of the American Medical Association JAMA: The Journal of the American Medical Association is an international peer-reviewed general medical journal, published 48 times per year by the American Medical Association. JAMA is the most widely circulated medical journal in the world. , The Lancelet lancelet, name for small, fishlike lower chordate (see Chordata), also called amphioxus; it shows many affinities with the vertebrates. There are about 30 lancelet species, most belonging to the genus Brachiostoma (formerly Amphioxus). and the British Medical Journal The British Medical Journal, or BMJ, is one of the most popular and widely-read peer-reviewed general medical journals in the world. It is published by the BMJ Publishing Group Ltd (owned by the British Medical Association), whose other . The CMAJ website receives about 1 million requests and 250,000 downloads per month. The Journal is part of the PubMed Central Collection of Journals at the National Library of Medicine in Washington, D.C
Principal Clinical Investigators:
Dr. Tapan Basu studied in the Department of Nutritional Biochemistry at the University of London For most practical purposes, ranging from admission of students to negotiating funding from the government, the 19 constituent colleges are treated as individual universities. Within the university federation they are known as Recognised Bodies and received his doctorate from the University of Surrey The University of Surrey is a public university in Guildford, England. It received its charter on 9 September 1966, and was situated near Battersea Park in south-west London. The institution was known as Battersea College of Technology before gaining university status. in 1971. He has written extensively on nutrition and pharmacology including 6 books and 158 papers and abstracts. He is or has been a member of advisory boards for professional publications like the British Journal of Nutrition and has played a key role in international conferences on clinical nutrition in six different countries. He holds 9 awards or honors for his work and has received research grants from five countries. He holds memberships in 12 professional societies including the British Society of Surgical Oncology and is a fellow of the American College of Nutrition.
Dr. Gerry Predy received his doctorate in medicine from the University of Alberta in 1976 and holds a Fellowship in the Royal College of Physicians The Royal College of Physicians of London was the first medical institution in England to receive a Royal Charter. It was founded in 1518 and is one of the most active of all medical professional organisations. and Surgeons (Canada) in Community Medicine. Since 1996 he's been the Medical Officer of Health for the Capital Health Region in Alberta - the largest integrated academic health region in Canada. He supervises 170 public health nurses, inspectors and health care workers involved in public health programs. He's the Director of the Northern Alberta Vaccine Trials and Evaluation Centre and has conducted research in a number of public health areas. He's also the former chair of the Council of Medical Officers of Health. Capital Health operates medical facilities including 10 hospitals and employs more than 18,000 health care workers.
CONTACT: MEDIA: Mr. Warren Michaels, Vice President, Communications, CV Technologies Inc., (780) 432-0022 ext 224, (dir) (780) 577-3710, (cell) (780) 499-1396, firstname.lastname@example.org, http://www.cvtechnologies.com/, http://www.coldfx.com/